

Alejandro Forner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6709136/alejandro-forner-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109
papers

28,322
citations

38
h-index

148
g-index

148
ext. papers

34,694
ext. citations

8.1
avg. IF

7.4
L-index

#	Paper	IF	Citations
109	Impact of Reference Standard on CT, MRI, and Contrast-enhanced US LI-RADS Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis.. <i>Radiology</i> , 2022 , 212340	20.5	0
108	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. <i>Cancers</i> , 2022 , 14, 2389	6.6	2
107	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. <i>Journal of Hepatology</i> , 2021 ,	13.4	10
106	CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. <i>Radiology</i> , 2021 , 211244	20.5	4
105	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
104	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. <i>Journal of Hepatology</i> , 2021 ,	13.4	127
103	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021 , 55, 263-270	3	2
102	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021 , 73, 2311-2325	11.2	13
101	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021 , 12, 440-449	3.3	0
100	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica</i> , 2021 , 156, 463.e1-463.e30	1	2
99	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021 , 156, 463.e1-463.e30	0.3	0
98	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021 , 3, 100260	0.3	11
97	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021 , 75, 1154-1163	13.4	3
96	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021 , 9, 655-661	5.3	1
95	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	2
94	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules \geq 1 cm in cirrhotic patients. <i>European Radiology</i> , 2021 , 31, 4794-4803	8	3
93	REPLY. <i>Hepatology</i> , 2021 , 74, 1129-1131	11.2	1

92	REPLY. <i>Hepatology</i> , 2021 , 74, 2319-2321	11.2	0
91	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy 2021 , 9,		6
90	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020 , 52, 1041-1046	3.3	7
89	Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma?. <i>Lancet Oncology, The</i> , 2020 , 21, 867-869	21.7	1
88	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588	24.2	355
87	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020 , 30, 6694-6701	8	3
86	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020 , 26, S1-S40	3	4
85	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 710-719	2.4	10
84	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. <i>Journal of Hepatology</i> , 2020 , 73, 1360-1367	13.4	7
83	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020 , 40, 2476-2488	7.9	1
82	Intention-to-treat curative liver resection in patients with "very early" intrahepatic cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2020 , 405, 967-975	3.4	2
81	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020 , 30, 186-194	8	11
80	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 482-491	6.1	30
79	Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules \geq 1 cm in cirrhosis. <i>Liver International</i> , 2019 , 39, 1281-1291	7.9	9
78	PS-115-Evaluation of LI-RADS v2018 by magnetic resonance in US-detected nodules <i>Journal of Hepatology</i> , 2019 , 70, e73	13.4	2
77	Clinical presentation, diagnosis and staging of cholangiocarcinoma. <i>Liver International</i> , 2019 , 39 Suppl 1, 98-107	7.9	77
76	Systemic doxorubicin and hepatocellular carcinoma: the end of an era never risen up. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 418-420	18.8	1
75	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019 , 1, 17-29	10.3	26

74	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019 , 72, 28-36	14.4	163
73	A rare cause of systemic inflammatory response syndrome. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 383-384	0.9	
72	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018 , 69, 182-236	13.4	3196
71	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018 , 391, 1301-1314	40	2402
70	Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. <i>Liver Transplantation</i> , 2017 , 23, 645-651	4.5	2
69	IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3195-3201	5.1	10
68	Surveillance for hepatocellular carcinoma. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2016 , 30, 1001-1010	2.5	15
67	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. <i>Hepatology</i> , 2016 , 63, 488-98	11.2	21
66	Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet. <i>Journal of Hepatology</i> , 2016 , 65, 648-9	13.4	2
65	New challenges in clinical research on hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016 , 108, 485-93	0.9	11
64	Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. <i>Hepatology</i> , 2016 , 63, 839-49	11.2	74
63	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016 , 146, 511.e1-511.e22	0.3	1
62	Does ramucirumab deserve a second chance for liver cancer?. <i>Lancet Oncology, The</i> , 2015 , 16, 751-2	21.7	3
61	Hepatocellular carcinoma surveillance with miRNAs. <i>Lancet Oncology, The</i> , 2015 , 16, 743-5	21.7	29
60	Intermediate-stage HCC--upfront resection can be feasible. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12,	19.4	6
59	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015 , 275, 698-707	20.5	99
58	Reply to: Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis! <i>Journal of Hepatology</i> , 2015 , 62, 1453-4	13.4	
57	Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 10	19.4	14

56	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules. <i>Journal of Hepatology</i> , 2015 , 62, 150-5	13.4	28
55	Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients 2014 , 77-93		
54	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 525-35	19.4	315
53	Prognosis prediction and staging. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 855-65	2.5	15
52	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014 , 61, 318-24	13.4	172
51	Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. <i>Seminars in Liver Disease</i> , 2014 , 34, 444-55	7.3	83
50	Consensus report of the Fifth International Forum for Liver MRI. <i>American Journal of Roentgenology</i> , 2013 , 201, 97-107	5.4	35
49	Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. <i>Hepatology</i> , 2013 , 58, 2023-31	11.2	162
48	The size of the problem: clinical algorithms. <i>Digestive Diseases</i> , 2013 , 31, 95-103	3.2	5
47	Evoluci3 natural y estratificaci3 del carcinoma hepatocelular. <i>Clinical Liver Disease</i> , 2013 , 2, S33-S36	2.2	78
46	Management of HCC. <i>Journal of Hepatology</i> , 2012 , 56 Suppl 1, S75-87	13.4	438
45	Hepatocellular carcinoma. <i>Lancet, The</i> , 2012 , 379, 1245-55	40	3423
44	Hepatocellular carcinoma [AuthorsPreply. <i>Lancet, The</i> , 2012 , 380, 470-471	40	26
43	Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. <i>Lancet Oncology, The</i> , 2012 , 13, e11-22	21.7	701
42	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012 , 1, 183-185	2.2	4
41	Chemoembolization for intermediate HCC: is there proof of survival benefit?. <i>Journal of Hepatology</i> , 2012 , 56, 984-6	13.4	89
40	Non-invasive diagnosis of hepatocellular carcinoma 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012 , 56, 1317-23	13.4	135
39	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012 , 56, 1330-5	13.4	354

38	Biomarkers for early diagnosis of hepatocellular carcinoma. <i>Lancet Oncology, The</i> , 2012 , 13, 750-1	21.7	86
37	Approach of the patient with a liver mass. <i>Frontline Gastroenterology</i> , 2012 , 3, 252-262	2.6	3
36	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. <i>Gut</i> , 2012 , 61, 1481-7	19.2	121
35	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. <i>Cancer Treatment Reviews</i> , 2011 , 37, 212-20	14.4	407
34	What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?. <i>Liver Transplantation</i> , 2011 , 17 Suppl 2, S26-33	4.5	15
33	Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. <i>Hepatology</i> , 2011 , 54, 2238-44	11.2	84
32	Current strategy for staging and treatment: the BCLC update and future prospects. <i>Seminars in Liver Disease</i> , 2010 , 30, 61-74	7.3	770
31	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010 , 42 Suppl 3, S242-8	3.3	27
30	Ablation for hepatocellular carcinoma: Is there need to have a winning technique?. <i>Journal of Hepatology</i> , 2010 , 52, 310-2	13.4	15
29	Addendum al artículo: «Técnicas de imagen en el carcinoma hepatocelular: diagnóstico, extensión y evaluación de la respuesta terapéutica». <i>Gastroenterología Y Hepatología</i> , 2010 , 33, 727-728	0.9	
28	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. <i>Annual Review of Medicine</i> , 2010 , 61, 317-28	17.4	189
27	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2010 , 10, 209	4.8	138
26	Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1239-44	2.2	16
25	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010 , 51, 2020-9	11.2	209
24	Reply:. <i>Hepatology</i> , 2010 , 52, 1516-1517	11.2	
23	East meets the West--portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009 , 6, 14-5		12
22	Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009 , 50, 791-8	11.2	207
21	Reply:. <i>Hepatology</i> , 2009 , 50, 1316-1317	11.2	

20	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. <i>Cancer</i> , 2009 , 115, 616-23	6.4	359
19	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009 , 29 Suppl 1, 148-58	7.9	19
18	Clinical research in hepatocellular carcinoma: study design and endpoints. <i>Journal of Hepatology</i> , 2009 , 50, 850-3	13.4	3
17	Transarterial therapies in HCC: does embolization increase survival?. <i>Journal of Hepatology</i> , 2009 , 51, 981-3	13.4	5
16	Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. <i>Gastroenterology</i> , 2009 , 137, 26-9	13.3	77
15	To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer?. <i>Gastroenterology</i> , 2009 , 137, 375-6; discussion 377	13.3	2
14	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology, The</i> , 2009 , 10, 35-43	21.7	1490
13	Sunitinib and the benefits of a negative study. <i>Lancet Oncology, The</i> , 2009 , 10, 743-4	21.7	8
12	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 378-90	59.2	9089
11	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , 2008 , 47, 97-104	11.2	718
10	Reply:. <i>Hepatology</i> , 2008 , 47, 2146-2147	11.2	8
9	Transarterial chemoembolization for patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2007 , 37 Suppl 2, S230-7	5.1	12
8	Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , 2007 , 46, 474-81	13.4	734
7	Treatment of hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, 89-98	7	123
6	Hepatocarcinoma y VHC. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 196-199	0.9	0
5	New aspects of diagnosis and therapy of hepatocellular carcinoma. <i>Oncogene</i> , 2006 , 25, 3848-56	9.2	125
4	Prognostic prediction in patients with hepatocellular carcinoma. <i>Seminars in Liver Disease</i> , 2005 , 25, 171-80	7.9	71
3	Ileal carcinoid tumor as a cause of massive lower-GI bleeding: the role of capsule endoscopy. <i>Gastrointestinal Endoscopy</i> , 2004 , 60, 483-5	5.2	15

2 Tumors of the Liver773-785

1 Malignant Tumours1437-1463

1